GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET)

Raffaella Depalo, K Jayakrishan, Gabriella Garruti, Ilaria Totaro, Mariantonietta Panzarino, Francesco Giorgino, Luigi E Selvaggi, Raffaella Depalo, K Jayakrishan, Gabriella Garruti, Ilaria Totaro, Mariantonietta Panzarino, Francesco Giorgino, Luigi E Selvaggi

Abstract

Several protocols are actually available for in Vitro Fertilization and Embryo Transfer. The review summarizes the main differences and the clinic characteristics of the protocols in use with GnRH agonists and GnRH antagonists by emphasizing the major outcomes and hormonal changes associated with each protocol. The majority of randomized clinical trials clearly shows that in "in Vitro" Fertilization and Embryo Transfer, the combination of exogenous Gonadotropin plus a Gonadotropin Releasing Hormone (GnRH) agonist, which is able to suppress pituitary FSH and LH secretion, is associated with increased pregnancy rate as compared with the use of gonadotropins without a GnRH agonist. Protocols with GnRH antagonists are effective in preventing a premature rise of LH and induce a shorter and more cost-effective ovarian stimulation compared to the long agonist protocol. However, a different synchronization of follicular recruitment and growth occurs with GnRH agonists than with GnRH antagonists. Future developments have to be focused on timing of the administration of GnRH antagonists, by giving a great attention to new strategies of stimulation in patients in which radio-chemotherapy cycles are needed.

Figures

Figure 1
Figure 1
GnRH agonist protocols. Long Protocol: GnRH agonist 0.1 mg starting in follicular phase or luteal phase (Cycle Day 21) of the previuos cycle until hCG administration . Short Protocol: GnRH agonist 0.1 mg starting on day 1 or 3 of stimulation until hCG administration. Ultrashort Protocol: GnRH agonist 0.1 mg administered on day 2–4 of stimulation.
Figure 2
Figure 2
GnRH antagonist protocols. Fixed day 6 protocol: 0.25 mg GnRH antagonist/daily until hCG administration (Albano et al.,F&S 1997)[23]. Single dose protocol. 3 mg GnRH antagonist at day 7 of stimulation (Olivennes et al.,HR 1998)[22]. Flexible dose protocol: 0.25 mg GnRH antagonist when follicles reach >14 mm (Diedrich et al., HR 1994).[21]
Figure 3
Figure 3
Linear regression analysis between patient’s age and number of oocytes in the GnRH agonist group (A) and the GnRH antagonist group (B). In GnRH antagonist protocol it was observed a positive correlation between number of oocytes and patient’s age: the luteo-follicular transition induces FSH levels above the treshold for a short-period until hormonal feedback occurs, leading to the initiation of follicular growth of a few leading follicle. After exogenous FSH administration, FSH levels arise above threshold again and will initiate several additional follicles to grow, leading to a less synchronization of the follicular cohort, and a more natural recruitment of follicles. In GnRH antagonist protocol no correlation was observed between number of follicles and patient’s age. In GnRH agonist protocol, FSH levels remain above the threshold following pituitary downregulation and FSH exogenous administration, resulting in a more synchronized follicular recruitment (Depalo et al., Gynecol Endocrinol. 2009).[45]

References

    1. Caspi E, Ron-El R, Golan A, Nachum H, Herman A, Soffer Y, Weinraub Z. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins. Fertil Steril. 1989;51(1):95–99.
    1. Liu HC, Lai YM, Davis O, Berkeley AS, Graf M, Grifo J, Cohen J, Rosenwaks Z. Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality. J Assist Reprod Genet. 1992;9(4):338–344. doi: 10.1007/BF01203956.
    1. Zorn JR, Boyer P, Guichard A. Never on a Sunday: programming for IVF-ET and GIFT. Lancet. 1987;1(8529):385–386.
    1. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000;2:CD001299.
    1. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev. 2005;1:CD002808.
    1. Lorusso F, Depalo R, Selvaggi L. Relationship between gonadotropin releasing hormone agonist dosage and in vitro fertilization outcome. Gynecol Endocrinol. 2004;18(2):69–73. doi: 10.1080/09513590310001651830.
    1. Conn PM, Staley D, Harris C, Andrews WV, Gorospe WC, McArdle CA. Mechanism of action of gonadotropin releasing hormone. Annu RevPhysiol. 1986;48:495–513.
    1. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod. 1992;7(3):320–327.
    1. Ben-Rafael Z, Lipitz S, Bider D, Mashiach S. Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril. 1991;55(2):272–275.
    1. Ron-El R, Herman A, Golan A, Raziel A, Soffer Y, Caspi E. Follicle cyst formation following long-acting gonadotropin-releasing hormone analog administration. Fertil Steril. 1989;52(6):1063–1066.
    1. Olivennes F, Frydman R. Friendly IVF: the way of the future? Hum Reprod. 1998;13(5):1121–1124. doi: 10.1093/humrep/13.5.1121.
    1. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22(11):2805–2813. doi: 10.1093/humrep/dem270.
    1. Al-Inany HG, Youssef MAFM, Aboulghar M, Broekmans FJ, Sterenburg MD, Smit JG, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews. 2011;5(11):CD001750.
    1. Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril. 2010;95(1):164–169.
    1. Humaidan P, Kol S, Papanikolaou EG. Copenhagen GnRH Agonist Triggering Workshop Group: GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;4:510–524. Review.
    1. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593–2597. doi: 10.1093/humrep/der251.
    1. Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online. 2010;20(6):783–788. doi: 10.1016/j.rbmo.2010.03.004.
    1. Cavagna M, Dzik A. Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report. Reprod Biomed Online. 2011;22(3):317–319. doi: 10.1016/j.rbmo.2010.11.015.
    1. von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women–a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284(2):427–435. doi: 10.1007/s00404-011-1874-1.
    1. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril. 1994;62(3):468–476.
    1. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788–791.
    1. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod. 1998;13(9):2411–2424. doi: 10.1093/humrep/13.9.2411.
    1. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67(5):917–922. doi: 10.1016/S0015-0282(97)81407-0.
    1. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) Hum Reprod. 1998;13(11):3023–3031.
    1. Wilcox J, Potter D, Moore M, Ferrande L, Kelly E. CAP IV Investigator Group: Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril. 2005;84(1):108–117. doi: 10.1016/j.fertnstert.2005.03.016.
    1. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) Fertil Steril. 2000;73(2):314–320. doi: 10.1016/S0015-0282(99)00524-5.
    1. Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM, Diedrich K. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod. 2002;17(11):2842–2845. doi: 10.1093/humrep/17.11.2842.
    1. Mochtar MH. Dutch Ganirelix Study Group. The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Hum Reprod. 2004;19(8):1713–1718. doi: 10.1093/humrep/deh334.
    1. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online. 2005;10(5):567–570. doi: 10.1016/S1472-6483(10)61661-6.
    1. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab. 2003;88(12):5632–5637. doi: 10.1210/jc.2003-030805.
    1. Escudero E, Bosch E, Crespo J, Simón C, Remohí J, Pellicer. A Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril. 2004;81(3):562–566. doi: 10.1016/j.fertnstert.2003.07.027.
    1. Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC. Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertil Steril. 2004;82(1):223–226. doi: 10.1016/j.fertnstert.2003.12.027.
    1. Cédrin-Durnerin I. Antagonist protocols: residual LH levels and the value of exogenous LH supplementation. J Gynecol Obstet Biol Reprod (Paris) 2004;33(6 Pt 2):3S29–3S31.
    1. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Théron L, Wolf JP, Conord C, Clément P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004;19(9):1979–1984. doi: 10.1093/humrep/deh369.
    1. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online. 2004;8(5):524–527. doi: 10.1016/S1472-6483(10)61098-X.
    1. Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J, Uzan S. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril. 2004;82(1):119–125. doi: 10.1016/j.fertnstert.2003.11.040.
    1. Baruffi RL, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, Cavagna M, Oliveira JB, Franco JG. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online. 2007;14(1):14–25. doi: 10.1016/S1472-6483(10)60758-4.
    1. Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, Homburg R, Lambalk CB. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod. 2005;20(2):359–367.
    1. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12(6):651–671. doi: 10.1093/humupd/dml038.
    1. Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril. 2010;94(6):2382–2384. doi: 10.1016/j.fertnstert.2010.04.025.
    1. Kosmas IP, Zikopoulos K, Gorgiou I, Paraskevaidis E, Blockeel C, Tournaye H, Van Der Elst J, Devroey P. Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis. Reprod Biomed Online. 2009;19(5):619–630. doi: 10.1016/j.rbmo.2009.09.007.
    1. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16(4):644–651. doi: 10.1093/humrep/16.4.644.
    1. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001;358(9295):1793–1803. doi: 10.1016/S0140-6736(01)06797-6.
    1. Engel JB, Griesinger G, Schultze-Mosgau A, Felberbaum R, Diedrich K. GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online. 2006;13(1):84–87. doi: 10.1016/S1472-6483(10)62019-6.
    1. Depalo R, Lorusso F, Palmisano M, Bassi E, Totaro I, Vacca M. et al.Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecol Endocrinol. 2009;25(5):328–334. doi: 10.1080/09513590802617762.
    1. Johnston-MacAnanny EB, DiLuigi AJ, Engmann LL, Maier DB, Benadiva CA, Nulsen JC. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols. J Reprod Med. 2011;56(1–2):12–26.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere